Literature DB >> 20966805

Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region.

Shin-E Wang1, Cheng-Hsi Su, Ying-Ju Kuo, Yi-Ming Shyr, Anna Fen-Yau Li, Tien-Hua Chen, Chew-Wun Wu, Chen-Hsen Lee.   

Abstract

OBJECTIVE: To present our experience of 93 neuroendocrine tumors (NETs) in the pancreas and peripancreatic region, with emphasis on how resectability affects long-term survival and the impact of functional status on the survival outcome.
METHODS: Ninety-three patients with NETs in the pancreas and peripancreatic region were included to compare the clinical features between functional and nonfunctional NETs. Prognostic factors were determined by univariate and multivariate analyses.
RESULTS: There were 39 functional (41.9%) and 54 nonfunctional NETs (58.1%). According to World Health Organization (WHO) tumor categories, there were 57 well-differentiated tumors (61.3%), 26 well-differentiated carcinomas (28%), and 10 poorly differentiated carcinomas (10.8%). Univariate analysis showed that functional status of the tumor, tumor stage, lymph node status, and pathological classification were prognostic factors for both disease-free survival and disease-specific survival. Resectability did not influence the survival outcome, with the resectable and unresectable groups demonstrating a 5-year disease-specific survival of 86.4% and 65.6%, respectively (P = 0.210). Only the WHO pathological classification was an independent prognostic factor after multivariate analysis.
CONCLUSIONS: Irresectability does not necessarily preclude long-term survival for both functional and nonfunctional NETs. It is the WHO pathological classification, instead of hormonal functional status, that is an independent prognostic factor and has impact on the survival outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20966805     DOI: 10.1097/MPA.0b013e3181f94cc4

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  14 in total

1.  The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis.

Authors:  Seong-Jang Kim; Kyoungjune Pak; Phillip J Koo; Jennifer J Kwak; Samuel Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-09       Impact factor: 9.236

Review 2.  Everolimus in the management of metastatic neuroendocrine tumours.

Authors:  David L Chan; Eva Segelov; Simron Singh
Journal:  Therap Adv Gastroenterol       Date:  2016-10-25       Impact factor: 4.409

3.  Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors.

Authors:  Ming-Huang Chen; Yi-Chen Yeh; Yi-Ming Shyr; Yi-Hua Jan; Yee Chao; Chung-Pin Li; Shin-E Wang; Cheng-Hwai Tzeng; Peter Mu-Hsin Chang; Chun-Yu Liu; Ming-Han Chen; Michael Hsiao; Chi-Ying F Huang
Journal:  J Gastroenterol       Date:  2012-06-16       Impact factor: 7.527

4.  Resection strategies for neuroendocrine pancreatic neoplasms.

Authors:  F M Watzka; C Laumen; C Fottner; M M Weber; A Schad; H Lang; T J Musholt
Journal:  Langenbecks Arch Surg       Date:  2012-11-11       Impact factor: 3.445

5.  Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas.

Authors:  De-shen Wang; Dong-sheng Zhang; Miao-zhen Qiu; Zhi-qiang Wang; Hui-yan Luo; Feng-hua Wang; Yu-hong Li; Rui-hua Xu
Journal:  Tumour Biol       Date:  2011-04-09

6.  Genomic landscape of pancreatic neuroendocrine tumors.

Authors:  Niklas Gebauer; Christian Schmidt-Werthern; Veronica Bernard; Alfred C Feller; Tobias Keck; Nehara Begum; Dirk Rades; Hendrik Lehnert; Georg Brabant; Christoph Thorns
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

7.  Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.

Authors:  Sara Krogh; Henning Grønbæk; Anders Riegels Knudsen; Peter Kissmeyer-Nielsen; Nynne Emilie Hummelshøj; Gitte Dam
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

8.  Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgically Resectable Pancreatic Neuroendocrine Tumors.

Authors:  Bo Zhou; Canyang Zhan; Jingjing Wu; Jianhua Liu; Jie Zhou; Shusen Zheng
Journal:  Med Sci Monit       Date:  2017-11-23

9.  Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center.

Authors:  Bo Zhou; Jixuan Duan; Sheng Yan; Jie Zhou; Shusen Zheng
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

Review 10.  Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review.

Authors:  Anneke P J Jilesen; Casper H J van Eijck; K H in't Hof; S van Dieren; Dirk J Gouma; Els J M Nieveen van Dijkum
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.